Literature DB >> 7914410

CD4+ and CD8+ T cell expansions using selected TCR V and J gene segments at the onset of giant cell arteritis.

J Grunewald1, R Andersson, L Rydberg, D Gigliotti, C Schaufelberger, G K Hansson, H Wigzell.   

Abstract

OBJECTIVE: To investigate T cell receptor (TCR) V alpha/V beta (and in selected cases, J beta) usage in CD4+ and CD8+ peripheral blood lymphocytes of patients with giant cell arteritis (GCA), before and after treatment, as well as to analyze the HLA types of these patients.
METHODS: Flow cytometry, with 10 anti-TCR V-specific monoclonal antibodies (MAb), was used. To analyze J beta usage by cell populations expressing certain V beta, we used the polymerase chain reaction (PCR) technique, with V beta- and C beta-specific primers, Southern blotting of PCR products, and subsequent hybridization with radiolabeled J beta-specific probes. HLA typing was performed using the microlymphocytotoxicity technique.
RESULTS: Seven of the 9 GCA patients had increased anti-TCR V MAb reactivities (interpreted as T cell expansions), which in many cases, correlated with clinical signs of disease. A strict preference for particular J beta segments was found in 3 of 3 expanded CD4+ T cell populations.
CONCLUSION: T lymphocytes expressing specific antigen receptors are implicated in the pathogenesis of GCA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7914410     DOI: 10.1002/art.1780370817

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  12 in total

Review 1.  T cell receptor usage in autoimmune disease.

Authors:  P Moss; J Bell
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Abnormal T cell receptor V gene usage in myasthenia gravis: prevalence and characterization of expanded T cell populations.

Authors:  B Y Xu; R Giscombe; A Söderlund; M Troye-Blomberg; R Pirskanen; A K Lefvert
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

Review 3.  Immune checkpoint dysfunction in large and medium vessel vasculitis.

Authors:  Ryu Watanabe; Hui Zhang; Gerald Berry; Jörg J Goronzy; Cornelia M Weyand
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-03-17       Impact factor: 4.733

4.  Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis.

Authors:  Hui Zhang; Ryu Watanabe; Gerald J Berry; Augusto Vaglio; Yaping Joyce Liao; Kenneth J Warrington; Jörg J Goronzy; Cornelia M Weyand
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-23       Impact factor: 11.205

Review 5.  IFN-γ and IL-17: the two faces of T-cell pathology in giant cell arteritis.

Authors:  Cornelia M Weyand; Brian R Younge; Jörg J Goronzy
Journal:  Curr Opin Rheumatol       Date:  2011-01       Impact factor: 5.006

6.  T cell receptor (TCR) V gene usage in patients with systemic necrotizing vasculitis.

Authors:  R Giscombe; J Grunewald; S Nityanand; A K Lefvert
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

7.  Selective T cell receptor decrease in peripheral blood T lymphocytes of patients with polymyalgia rheumatica and giant cell arteritis.

Authors:  M Lopez-Hoyos; M J Bartolome-Pacheco; R Blanco; V Rodriguez-Valverde; V M Martinez-Taboada
Journal:  Ann Rheum Dis       Date:  2004-01       Impact factor: 19.103

8.  Restricted usage of T cell receptor V alpha/J alpha gene segments with different nucleotide but identical amino acid sequences in HLA-DR3+ sarcoidosis patients.

Authors:  J Grunewald; T Hultman; A Bucht; A Eklund; H Wigzell
Journal:  Mol Med       Date:  1995-03       Impact factor: 6.354

9.  Expanded T cell populations in patients with Wegener's granulomatosis: characteristics and correlates with disease activity.

Authors:  R Giscombe; S Nityanand; N Lewin; J Grunewald; A K Lefvert
Journal:  J Clin Immunol       Date:  1998-11       Impact factor: 8.317

10.  An uneven expression of T cell receptor V genes in the arterial wall and peripheral blood in giant cell arteritis.

Authors:  C Schaufelberger; R Andersson; E Nordborg; G K Hansson; C Nordborg; J Wahlström
Journal:  Inflammation       Date:  2008-12       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.